A method for production of a mutant-type human erythropoietin comprising the amino acid sequence set forth as SEQ ID NO:2, the method comprising; (a) a step of providing a mutant-type human erythropoietin-producing mammalian cell which produces the mutant-type human erythropoietin, (b) a step of culturing the mutant-type human erythropoietin-producing mammalian cell in a serum-free medium to let the cell secrete the mutant-type human erythropoietin into the culture, (c) a step of preparing a supernatant by removing the cell from the culture, (d) a step of subjecting the supernatant to hydrophobic column chromatography to collect a fraction, the fraction being not adsorbed by the column and containing the mutant-type human erythropoietin, wherein before the culture supernatant is applied to the column, the electrical conductivity of the culture supernatant is adjusted to not less than 15 S/m, by addition of a neutral salt, and the pH thereof is adjusted to 7.0-8.0, and the hydrophobic column is equilibrated in advance with 15-25 mM Tris buffer adjusted to pH 7.0-8.0 and containing 1.5 M-2.5 M neutral salt, (e) a step of subjecting the fraction collected in the directly preceding step to multimodal anion exchange column chromatography to collect a fraction containing the mutant-type human erythropoietin, (f) a step of subjecting the fraction collected in the directly preceding step to anion exchange column chromatography to collect a fraction containing the mutant-type human erythropoietin, (g) a step of subjecting the fraction collected in the directly preceding step to column chromatography that employs a solid-phase material having affinity to phosphate group to collect a fraction containing the mutant-type human erythropoietin, and (h) a step of subjecting the fraction collected in the directly preceding step to gel filtration column chromatography to collect a fraction containing the mutant-type human erythropoietin, in this order. (a) a step of providing a mutant-type human erythropoietin-producing mammalian cell which produces the mutant-type human erythropoietin, (b) a step of culturing the mutant-type human erythropoietin-producing mammalian cell in a serum-free medium to let the cell secrete the mutant-type human erythropoietin into the culture, (c) a step of preparing a supernatant by removing the cell from the culture, (d) a step of subjecting the supernatant to hydrophobic column chromatography to collect a fraction, the fraction being not adsorbed by the column and containing the mutant-type human erythropoietin, wherein before the culture supernatant is applied to the column, the electrical conductivity of the culture supernatant is adjusted to not less than 15 S/m, by addition of a neutral salt, and the pH thereof is adjusted to 7.0-8.0, and the hydrophobic column is equilibrated in advance with 15-25 mM Tris buffer adjusted to pH 7.0-8.0 and containing 1.5 M-2.5 M neutral salt, (e) a step of subjecting the fraction collected in the directly preceding step to multimodal anion exchange column chromatography to collect a fraction containing the mutant-type human erythropoietin, (f) a step of subjecting the fraction collected in the directly preceding step to anion exchange column chromatography to collect a fraction containing the mutant-type human erythropoietin, (g) a step of subjecting the fraction collected in the directly preceding step to column chromatography that employs a solid-phase material having affinity to phosphate group to collect a fraction containing the mutant-type human erythropoietin, and (h) a step of subjecting the fraction collected in the directly preceding step to gel filtration column chromatography to collect a fraction containing the mutant-type human erythropoietin,